Whole-Body-MR-Diffusion weighted imaging in oncology

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 185, Issue 10, 2013, Pages 950-958

  Wilhelm, Thomas ^a   Stieltjes, B ^a   Schlemmer, H P ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

metastases; MR diffusion perfusion; treatment effects

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; BONE MARROW; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DIFFUSION WEIGHTED IMAGING; HUMAN; LYMPH VESSEL; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; STANDARDIZATION; TUMOR VOLUME; WHOLE BODY MRI;

EID: 84885060916     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0033-1335428     Document Type: Article

References (60)

1. Schlemmer H. P. et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol: 2005; 40 64 71
2. Ruehm S. G. et al. Whole-body MRA on a rolling table platform (AngioSURF). Fortschr Röntgenstr: 2000; 172 670 674
3. Eustace S. et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. Am J Roentgenol: 1997; 169 1655 1661 (Pubitemid 127469800)
4. Jones S. C. et al. Magnetic resonance diffusion-weighted imaging: sensitivity and apparent diffusion constant in stroke. Acta Neurochir Suppl: 1994; 60 207 210
5. Koh D. M., Collins D. J. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol: 2007; 188 1622 1635 (Pubitemid 46866868)
6. Takahara T. et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med: 2004; 22 275 282 (Pubitemid 39264807)
7. Kwee T. C. et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol: 2008; 18 1937 1952
8. Curvo-Semedo L. et al. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging: 2012; 35 1365 1371
9. Padhani A. R. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia: 2009; 11 102 125
10. Sankowski A. J. et al. The clinical value of MRI using single-shot echoplanar DWI to identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit: 2012; 18 MT33 MT40
11. Hamstra D. A., Rehemtulla A., Ross B. D. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol: 2007; 25 4104 4109 (Pubitemid 47495868)
12. Laun F. B. et al. Introduction to the basic principles and techniques of diffusion-weighted imaging. Radiologe: 2011; 51 170 179
13. Padhani A. R., Koh D. M., Collins D. J. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology: 2011; 261 700 718
14. Le Bihan D. et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology: 1986; 161 401 407 (Pubitemid 17173295)
15. Lenz C. et al. Assessing extracranial tumors using diffusion-weighted whole-body MRI. Z Med Phys: 2011; 21 79 90
16. Ballon D. et al. Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med: 2004; 52 1234 1238 (Pubitemid 39612810)
17. Hwang S., Panicek D. M. Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol: 2007; 36 1017 1027 (Pubitemid 47498146)
18. Goodsitt M. M. et al. The composition of bone marrow for a dual-energy quantitative computed tomography technique. A cadaver and computer simulation study. Invest Radiol: 1994; 29 695 704 (Pubitemid 24258265)
19. Hausmann D. et al. Whole-body MRI in preoperative diagnostics of breast cancer - a comparison with [corrected] staging methods according to the S 3 guidelines. Fortschr Röntgenstr: 2011; 183 1130 1137
20. Messiou C. et al. Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol: 2011; 21 1713 1718
21. Ley S. et al. Neuroblastoma imaging. Fortschr Röntgenstr: 2011; 183 217 225
22. Manenti G. et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med: 2008; 113 199 213 (Pubitemid 351666954)
23. Woodfield C. A. et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol: 2010; 194 W316 W322
24. Kwee T. C. et al. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol: 2010; 75 215 220
25. Thoeny H. C. et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol: 2009; 55 761 769
26. Lin G. et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging: 2008; 28 128 135 (Pubitemid 351956475)
27. Bonekamp S., Corona-Villalobos C. P., Kamel I. R. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging: 2012; 35 257 279
28. Ono K. et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging: 2009; 29 336 340
29. Chen Y. et al. The clinical application of whole-body diffusion-weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging: 2012; 30 165 170
30. Yagci A. B. et al. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol: 2011; 17 130 134
31. Thormer G. et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol: 2012; 22 1820
32. Hilario A. et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. Am J Neuroradiol: 2012; 33 701 707
33. Lambregts D. M. et al. Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol: 2011; 21 2567 2574
34. Nakanishi M. et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol: 2012; 19 1302 1309
35. Moffat B. A. et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A: 2005; 102 5524 5529 (Pubitemid 40530291)
36. Patterson D. M., Padhani A. R., Collins D. J. Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol: 2008; 5 220 233 (Pubitemid 351493681)
37. Paran Y. et al. Water diffusion in the different microenvironments of breast cancer. NMR Biomed: 2004; 17 170 180 (Pubitemid 39089244)
38. Sun Y. S. et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology: 2010; 254 170 178
39. Dzik-Jurasz A. et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet: 2002; 360 307 308 (Pubitemid 34874724)
40. Byun W. M. et al. Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. Am J Neuroradiol: 2002; 23 906 912 (Pubitemid 34663429)
41. Ballon D. et al. Bone marrow segmentation in leukemia using diffusion and T (2) weighted echo planar magnetic resonance imaging. NMR Biomed: 2000; 13 321 328
42. Reischauer C. et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps - initial observations. Radiology: 2010; 257 523 531
43. Messiou C., de Souza N. M. Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. Cancer Biomark: 2010; 6 21 32
44. Hayashida Y. et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol: 2006; 16 2637 2643 (Pubitemid 44823917)
45. Cui Y. et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology: 2008; 248 894 900
46. De Keyzer F. et al. Dynamic contrast-enhanced and diffusion-weighted MRI for early detection of tumoral changes in single-dose and fractionated radiotherapy: evaluation in a rat rhabdomyosarcoma model. Eur Radiol: 2009; 19 2663 2671
47. Larocque M. P. et al. Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model. Phys Med Biol: 2010; 55 1381 1393
48. Jung S. H. et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging: 2012; 35 110 116
49. Kwee T. C. et al. Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol: 2009; 70 409 417
50. Kawamura E. et al. Clinical role of FDG-PET for HCC: relationship of glucose metabolic indicator to Japan Integrated Staging (JIS) score. Hepatogastroenterology: 2008; 55 582 586 (Pubitemid 351741506)
51. Picchio M. et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. Am J Roentgenol: 2002; 179 482 484 (Pubitemid 34785658)
52. Gulyas B., Nyary I., Borbely K. FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues. Nat Clin Pract Neurol: 2008; 4 470 471
53. Kwee T. C. et al. Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med: 2010; 51 1549 1558
54. Mori T. et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol: 2008; 3 358 364 (Pubitemid 351489475)
55. Ho K. C. et al. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging: 2009; 36 200 208
56. Schwenzer N. F. et al. Application of MR/PET in oncologic imaging. Fortschr Röntgenstr: 2012; 184 780 787
57. Padhani A. R., Miles K. A. Multiparametric imaging of tumor response to therapy. Radiology: 2010; 256 348 364
58. Smith-Bindman R. Is computed tomography safe? N Engl J Med: 2010; 363 1 4
59. Schaefer J. F., Kramer U. Whole-body MRI in children and juveniles. Fortschr Röntgenstr: 2011; 183 24 36
60. Klasen J., Antoch G., Blondin D. MR imaging of the abdomen in pregnancy. Fortschr Röntgenstr: 2011; 183 514 522